Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation

Clinical Transplantation

Volumn 21, Issue 1, 2007, Pages 47-56

  Barocci, Sergio ^a   Valente, Umberto ^a   Nocera, Arcangelo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Anti human leukocyte antigen (HLA) class I (A,B) and class II (DR,DQ) antibodies; Cross reactive groups (CREGS); Kidney retransplantation; Multispecific alloantibodies; Private epitopes; Sensitized dialysis patients

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; BLOOD ANALYSIS; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS REACTION; DONOR SELECTION; FEMALE; HEMODIALYSIS PATIENT; HLA MATCHING; HOSPITAL ADMISSION; HUMAN; ITALY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE;

ADULT; CADAVER; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-D ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RENAL DIALYSIS; REOPERATION; T-LYMPHOCYTES; TISSUE DONORS; WAITING LISTS;

EID: 33846684379     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00578.x     Document Type: Article

References (26)

1. Cecka JM. The role of HLA in renal transplantation. Hum Immunol 1997: 56: 6.
2. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002: 73: 1269.
3. Lee KW, Kim SJ, Lee DS et al. Effect of panel-reactive antibody positivity on graft rejection before or after kidney transplantation. Transplant Proc 2004: 36: 2009.
4. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003: 3: 665.
5. El-Awar N, Terasaki PI, Lazda V et al. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies. Transplant Proc 2002: 34: 2531.
6. Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002: 74: 1192.
7. Harmer AW, Koffman CG, Heads AJ, Vaughan RW. Sensitization to HLA antigens occurs in 95% of primary renal transplant rejections. Transplant Proc 1995: 27: 666.
8. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987: 7: 229.
9. Laundy GL, Bradley BA. The predictive value of epitope analysis in highly sensitized patients awaiting renal transplantation. Transplantation 1995: 59: 1207.
10. Rodey GE, Neylan JF, Whelchel J, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994: 39: 272.
11. Fuggle SV, Martin S. Toward performing transplantation in highly sensitized patients. Transplantation 2004: 78: 186.
12. Barocci S, Valente U, Gusmano R et al. Autoreactive lymphocytotoxic IgM antibodies in highly sensitized dialysis patients waiting for a kidney transplant: Identification and clinical relevance. Clin Nephrol 1991: 36: 12.
13. Rodey G. An approach to HLA specificity analysis. In: R odey G, ed. HLA Beyond Tears. Introduction to Human Histocompatibility. Durango: De Novo, Inc., 2000: 169-191.
14. Monteiro F, Buelow R, Mineiro C, Rodrigues H, Kalil J. Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Transplantation 1997: 63: 542.
15. Costa AN, Scolari MP, Iannelli S et al. The presence of postransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 1997: 63: 167.
16. van Kampen CA, Versteeg-van der Voort Maarschalk MF, Roelen DL, ten Berge IJ, C laas FH. Rejection of a kidney transplant does not always lead to priming of cytotoxic T cells against mismatched donor HLA class I antigens. Transplantation 2001: 71: 869.
17. Schönemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies: Monitoring before and after kidney transplantation and their clinical relevance. Transplantation 1998: 65: 1519.
18. Reinsmoen N, Kaestner S, Harland R, Matas AJ, Ward FE. Increased risk of acute and chronic rejection in sensitized kidney recipients with HLA class II-directed donor antigen-specific antibodies. In: T erasaki PI, ed. Visuals of the Clinical Histocompatibility Workshop: Palm Springs Invitational. California: OneLambda, Inc. 1999: 12.
19. Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 2001: 71: 652.
20. Fernandez-Fresnedo G, Pastor. JM, Lopez-Hoyos M et al. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrol Dial Transplant 2003: 18: 990.
21. Susal C, Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Hum Immunol 2004: 65: 810.
22. Piazza A, Poggi E., Ozzella G et al. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: Alloantibody characterization by flow cytometry techniques. Transplantation 2006: 81: 1298.
23. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887.
24. Gloor JM, De Goey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003: 3: 1017.
25. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002: 2: 758.
26. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256.